{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T15:24:20Z","timestamp":1791559460904,"version":"4.3.4"},"reference-count":31,"publisher":"Wiley","issue":"2","license":[{"start":{"date-parts":[[2023,10,4]],"date-time":"2023-10-04T00:00:00Z","timestamp":1696377600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Acad Dermatol Venereol"],"published-print":{"date-parts":[[2024,2]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Cancer risk after long\u2010term exposure to interleukin (IL)\u201023 inhibitors (IL\u201023i) and IL\u201017 inhibitors (IL\u201017i) remains to be delineated.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>To evaluate the risk of malignancies in patients with psoriasis treated with IL\u201023i and IL\u201017i relative to those prescribed tumour necrosis factor inhibitors (TNFi) during the first 5\u2009years following drug initiation.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      A global population\u2010based cohort study included two distinct analyses comparing patients with psoriasis under different therapeutic modalities; (i) new users of IL\u201017i(n\u2009=\u200915,331) versus TNFi (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u200915,331) and (ii) new users of IL\u201023i (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u20095832) versus TNFi (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u20095832).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Patients prescribed IL\u201017i experienced a decreased risk of non\u2010Hodgkin lymphoma (NHL; HR, 0.58; 95% CI, 0.40\u20130.82;\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.002), colorectal cancer (HR, 0.68; 95% CI, 0.49\u20130.95;\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.024), hepatobiliary cancer (HR, 0.68; 95% CI, 0.58\u20130.80;\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.001), ovary cancer (HR, 0.48; 95% CI, 0.29\u20130.81;\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.005), melanoma (HR, 0.52; 95% CI, 0.37\u20130.73;\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.001), and basal cell carcinoma (BCC; HR, 0.57; 95% CI, 0.48\u20130.67;\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.001). IL\u201023i was associated with a reduced risk of NHL (HR, 0.39; 95% CI, 0.19\u20130.78;\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.006), hepatobiliary cancer (HR, 0.44; 95% CI, 0.31\u20130.62;\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.001) and BCC (HR, 0.76; 95% CI, 0.57\u20130.99;\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.046). In a sensitivity analysis comparing patients managed by IL\u201017i and IL\u201023i with their biologic\u2010na\u00efve counterparts, these classes were associated with decreased risk of several malignancies.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>IL\u201017i and IL\u201023i are associated with decreased risk of several malignancies. These findings should be considered prior to the prescription of biologics.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1111\/jdv.19520","type":"journal-article","created":{"date-parts":[[2023,9,20]],"date-time":"2023-09-20T21:50:50Z","timestamp":1695246650000},"page":"315-324","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":39,"title":["Are interleukin 17 and interleukin 23 inhibitors associated with malignancies?\u2014Insights from an international population\u2010based study"],"prefix":"10.1111","volume":"38","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9971-9151","authenticated-orcid":false,"given":"Khalaf","family":"Kridin","sequence":"first","affiliation":[{"name":"L\u0171beck Institute of Experimental Dermatology University of L\u00fcbeck  L\u00fcbeck Germany"},{"name":"Azrieli Faculty of Medicine Bar\u2010Ilan University  Safed Israel"},{"name":"Unit of Dermatology and Skin Research Laboratory Galilee Medical Center  Nahariya Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariam","family":"Abdelghaffar","sequence":"additional","affiliation":[{"name":"School of Medicine Royal College of Surgeons in Ireland  Busaiteen Bahrain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noor","family":"Mruwat","sequence":"additional","affiliation":[{"name":"Unit of Dermatology and Skin Research Laboratory Galilee Medical Center  Nahariya Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ralf J.","family":"Ludwig","sequence":"additional","affiliation":[{"name":"L\u0171beck Institute of Experimental Dermatology University of L\u00fcbeck  L\u00fcbeck Germany"},{"name":"Department of Dermatology University of L\u00fcbeck  L\u00fcbeck Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diamant","family":"Tha\u00e7i","sequence":"additional","affiliation":[{"name":"Institute and Comprehensive Center for Inflammation Medicine University of L\u00fcbeck  L\u00fcbeck Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2023,10,4]]},"reference":[{"key":"e_1_2_9_2_1","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.12165"},{"key":"e_1_2_9_3_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2019.3056"},{"key":"e_1_2_9_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(00)04046-0"},{"key":"e_1_2_9_5_1","doi-asserted-by":"publisher","DOI":"10.1042\/BJ20141337"},{"key":"e_1_2_9_6_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.16715"},{"key":"e_1_2_9_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clindermatol.2009.03.003"},{"key":"e_1_2_9_8_1","doi-asserted-by":"publisher","DOI":"10.3348\/kjr.2015.16.2.286"},{"key":"e_1_2_9_9_1","doi-asserted-by":"publisher","DOI":"10.1002\/sim.6004"},{"key":"e_1_2_9_10_1","doi-asserted-by":"publisher","DOI":"10.1111\/1523-1747.ep12292698"},{"key":"e_1_2_9_11_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.15830"},{"key":"e_1_2_9_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2010.09.734"},{"key":"e_1_2_9_13_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.20136"},{"key":"e_1_2_9_14_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2016.03.024"},{"key":"e_1_2_9_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2014.01.025"},{"key":"e_1_2_9_16_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1501646"},{"key":"e_1_2_9_17_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2016.11.041"},{"key":"e_1_2_9_18_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(17)31279-5"},{"key":"e_1_2_9_19_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.13932"},{"key":"e_1_2_9_20_1","doi-asserted-by":"publisher","DOI":"10.1038\/nature14175"},{"key":"e_1_2_9_21_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2015.01.018"},{"key":"e_1_2_9_22_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1607017"},{"key":"e_1_2_9_23_1","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20190297"},{"key":"e_1_2_9_24_1","doi-asserted-by":"publisher","DOI":"10.1038\/nature14282"},{"key":"e_1_2_9_25_1","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20131195"},{"issue":"2","key":"e_1_2_9_26_1","first-page":"1","article-title":"The correlations between IL\u201017 vs. Th17 cells and cancer patient survival: a systematic review","volume":"4","author":"Punt S","year":"2015","journal-title":"Onco Targets Ther"},{"key":"e_1_2_9_27_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cyto.2018.04.017"},{"key":"e_1_2_9_28_1","doi-asserted-by":"publisher","DOI":"10.2147\/CMAR.S161248"},{"key":"e_1_2_9_29_1","doi-asserted-by":"publisher","DOI":"10.4103\/0973-1482.235345"},{"key":"e_1_2_9_30_1","doi-asserted-by":"publisher","DOI":"10.1038\/nature04808"},{"key":"e_1_2_9_31_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1003251107"},{"key":"e_1_2_9_32_1","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-12-1337"}],"container-title":["Journal of the European Academy of Dermatology and Venereology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/jdv.19520","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,3]],"date-time":"2024-09-03T05:16:47Z","timestamp":1725340607000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/jdv.19520"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10,4]]},"references-count":31,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2024,2]]}},"alternative-id":["10.1111\/jdv.19520"],"URL":"https:\/\/doi.org\/10.1111\/jdv.19520","archive":["Portico"],"relation":{},"ISSN":["0926-9959","1468-3083"],"issn-type":[{"value":"0926-9959","type":"print"},{"value":"1468-3083","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,10,4]]},"assertion":[{"value":"2023-04-05","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-09-06","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-10-04","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}